Analyst Rating Update on Dynavax Technologies Corporation (DVAX)

Dynavax Technologies Corporation (NASDAQ:DVAX) : 4 analysts are covering Dynavax Technologies Corporation (NASDAQ:DVAX) and their average rating on the stock is 2, which is read as a Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Dynavax Technologies Corporation (NASDAQ:DVAX) : The consensus price target for Dynavax Technologies Corporation (NASDAQ:DVAX) is $32.25 for the short term with a standard deviation of $14.86. The most optimist securities analyst among the 4 who monitor the stock believes that the stock can reach $45, however, the pessimist price target for the company is $17.

For the current week, the company shares have a recommendation consensus of Buy.

Dynavax Technologies Corporation (NASDAQ:DVAX): stock turned positive on Tuesday. Though the stock opened at $13.45, the bulls momentum made the stock top out at $14.01 level for the day. The stock recorded a low of $13.45 and closed the trading day at $13.69, in the green by 3.71%. The total traded volume for the day was 795,264. The stock had closed at $13.2 in the previous days trading.

In an insider trading activity, Gray Eddie, CEO of Dynavax Technologies Corp, executed a transaction worth $42,818 on May 20, 2016. A total of 2,750 shares were purchased at an average price of $15.57. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.